Inactive Instrument

Jupiter Neurosciences, Inc.

Equities

JUNS

US48208B2034

Biotechnology & Medical Research

Jupiter Neurosciences, Inc. Announces New Corporate Offices

September 21, 2021 at 06:19 pm IST

Jupiter Neurosciences, Inc. announced that the Company headquarters has moved to a new location, 1001 North US HWY 1, Suite #504, Jupiter, FL 33477. Additionally, Jupiter has established an office at 127 Main Street, Boston, MA 02129.

Latest news about Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL in Parkinson's Disease	27/23/27	CI
Jupiter Neurosciences, Inc. Appoints Saleem Elmasri as Chief Financial Officer	12/23/12	CI
Jupiter Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/22/03	CI
Jupiter Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	17/22/17	CI
Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting Use of JOTROL™	14/22/14	CI
Jupiter Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	19/22/19	CI
Jupiter Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	26/22/26	CI
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	26/22/26	CI
Jupiter Neurosciences, Inc. Announces Broadening of IP Estate for its Unique Resveratrol Formulation, JOTROL	01/22/01	CI
Jupiter Neurosciences, Inc. Announces Completion of Phase I Safety Trial with Enhanced Resveratrol Product, JOTROL™	23/22/23	CI
Jupiter Neurosciences to Issue 2.2 Million Units in IPO	27/22/27	MT
Jupiter Neurosciences, Inc. has filed an IPO.	12/21/12	CI
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	12/21/12	CI
Jupiter Neurosciences, Inc. Announces New Corporate Offices	21/21/21	CI

Chart Jupiter Neurosciences, Inc.

Duration

Period

More charts

Company Profile

Jupiter Neurosciences, Inc., formerly Jupiter Orphan Therapeutics, Inc., is a clinical stage research and development pharmaceutical company. The Company develops a resveratrol platform product targeting treatment of neuro-inflammation. The Company's product candidate, JOTROL, which primarily targets mucopolysaccharidoses Type 1, Friedreich's Ataxia, and MELAS as well as amyotrophic lateral sclerosis (ALS) which is in an early development stage. The JOTROL delivery platform allows resveratrol to be consumed in a soft gel capsule form. It offers therapeutic benefit to central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases. It targets Mild Cognitive Impairment/early Alzheimer's disease with traumatic brain injury (TBI)/concussions and Covid-19 in early development stages. The Company's product candidate, JOTROL, is in Phase I clinical trial.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+39.86%	5.37TCr
LONZA GROUP AG	+33.67%	3.89TCr
IQVIA HOLDINGS INC.	-8.26%	3.88TCr
CELLTRION, INC.	-10.77%	2.73TCr
ICON PUBLIC LIMITED COMPANY	+11.60%	2.59TCr
ALNYLAM PHARMACEUTICALS, INC.	-15.98%	2.03TCr
UNITED THERAPEUTICS CORPORATION	+33.93%	1.28TCr
MEDPACE HOLDINGS, INC.	+28.84%	1.22TCr
BIO-TECHNE CORPORATION	-2.89%	1.2TCr

Other Biotechnology & Medical Research